FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $96.1 million versus the consensus estimate of $97.19 million.
GUIDANCE:
Corcept Therapeutics sees FY2021 revenue of $365-375 million, versus the consensus... More

